Congress caps insulin at $35 for young people—closing a gap left by Medicare
H.R. 2636 — Making Insulin Affordable for All Children Act · Filed by Greg Landsman (D-OH) · 9 cosponsors · Introduced Apr 3, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill caps insulin costs for people under 26 with private health insurance at $35 per 30-day supply (or 25% of the negotiated price, whichever is lower) starting January 2026, with no deductibles allowed. It requires plans to cover at least one insulin product in each major type and dosage form, and applies to group plans, individual plans, and catastrophic plans under federal law.
Why we flagged it
The bill's sole functional purpose is to reduce out-of-pocket insulin costs for a vulnerable population (young people with diabetes) by imposing a price ceiling on private insurance plans. It is straightforward public health regulation, not a tax provision, subsidy, or commemorative measure.
What the text implies
- Pharmacy benefit managers (PBMs) may face pressure to reduce rebates or negotiate differently, potentially shifting costs upstream to manufacturers or reducing their own margins.
- Plans may respond by narrowing formularies (the list of covered drugs) to the minimum required—one product per type—reducing choice for young patients.
The full analysis lists 5 implications of this text.
Who stands to gain
young people with diabetes (primary beneficiary, not a financial entity); potentially pharmacy benefit managers if rebate structures shift favorably